Sanofi reports 2nd-qtr results, raises guidance; Dupixent strong out of the gates

31 July 2017

France’s Sanofi (Euronext: SAN) has raised its financial guidance for the year, referring to strong growth in its consumer healthcare and vaccines businesses, as well as at US biotech subsidiary Genzyme.

Announcing its financial results for the second quarter, Sanofi said net revenue stood at 8.6 billion euros ($10.1 billion), following generally accepted accounting principles (GAAP). That represents a 6.4% increase on the same period last year, roughly in line with what analysts had expected.

Net income, which the company reports on a non-GAAP basis, was up 1% for the quarter, at 1.7 billion euros, making the earnings per share figure 1.35 euros, a 3% increase.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK